Curtis Cole, PhD Curtis Cole, PhD, from Johnson & Johnson Consumer Products, is a leading expert on sunscreens and has spent his life’s work on sunscreen technology and formulation. In this presentation, Dr Cole leads a discussion on what every dermatologist needs to know about the current status of sunscreens. If sunscreens are so good […]
Andrew Blauvelt, MD, MBA Practical immunology is important for dermatologists to understand as it relates to a wide variety of pipeline drugs currently under investigation. In Dr Blauvelt’s view, there are three major cell types involved in psoriasis pathogenesis: 1) dendritic cells (upstream/initiating immune responses); 2) T cells (making pro-inflammatory cytokines); and 3) keratinocytes. Targeting […]
Andrew Blauvelt, MD, MBA Immunodermatology is an important content area for dermatologists to consider when managing patients with psoriasis. The genetics of psoriasis has been an exciting and complex area of research over the last few years, especially in terms of how genetics relate to the immunology of psoriasis. A recent paper highlighted how psoriasis […]
Kenneth Gordon, MD Small molecules were the mainstay for systemic psoriasis therapy for about forty years. Many patients would say that they prefer small molecules, i.e., a pill to a shot and, in fact, sometimes physicians feel more comfortable with a pill as well. In the last decade; however, all attention with regards to the […]
Craig Leonardi, MD It is crucial that dermatologists recognize the major advances in the management of psoriasis. Psoriasis affects approximately one to two percent of the general population in the United States, plaque psoriasis being the most common form accounting for approximately 90 percent of all cases. It is important to look at where dermatologists […]
High Risk Squamous Cell Carcinoma Marc Brown, MD In this presentation, Dr Brown discusses high risk squamous cell carcinomas. Dr Brown comments that this is the tumor than worries him more than any others. Introduction Squamous cell carcinoma (SCC) is the second most common type of cancer and more than 250,000 new cases are reported […]
Arthur Kavanaugh, MD There are many potential therapies currently under development for the treatment of psoriatic arthritis (PsA) and appear to fall under two categories: biologic agents and oral agents (kinase/enzyme inhibitors). Th Cell Development Th17 cells are elevated in PsA patients. One of the exciting areas of research now is that of […]
Actinic Keratoses George Martin, MD Unfortunately, field therapy for the treatment of AKs continues to remain underutilized in clinical practice even though we have a number of therapies available. Recent studies on dermatologist treatment practices demonstrate that 92% of patients treated for actinic damage are treated with cryotherapy alone; 7% with cryotherapy plus a prescription […]
Viral Skin Carcinogenesis Eggert Stockfleth, MD Dr Stockfleth reviewed the latest data and the role of the human papillomavirus (HPV) in skin cancer. HPV is a very stable, host-specific virus, which it is why it is referred to as “human” papillomaviruses. HPV is a frequent virus in most everyone. The most known strains of HPV […]
Part 1 Ted Rosen, MD Rayos Modified release prednisone (Rayos) is now on the market. Why would this be a reasonable therapeutic choice for healthcare providers? It’s important to remember that for many inflammatory diseases, proinflammatory cytokines peak overnight; yet, steroid administration is often administered in the morning. This treatment delays the bioavailability for about four hours. […]
Administrative Office
Maui Derm
161 Wailea Ike Place, Suite A-104
Kihei, HI 96753
Stay Connected
Sign up to receive updates about upcoming meetings.